The study results included data from a 464-patient randomized, double-blind, four-week, Phase IIb study that evaluated both the efficacy and tolerability of once-daily aclidinium (25mcg, 50mcg, 100mcg, 200mcg
The study will focus on men who have been referred to urologist and subsequently have been selected for a prostate biopsy, but will be restricted to men who
This Phase II study is a multi-center, randomized, double-blind, controlled study in patients with complicated skin and skin structure infections (cSSSI) presumed to be caused by gram-positive pathogens.
Richard Domanik, president and COO of CytoCore, said: “QuantRx will be our exclusive manufacturer for this product, which allows us to introduce a new paradigm in cytology sample
The study is placebo-controlled and double-blinded, and will include up to five cohorts receiving escalating doses. As many as 35 subjects will be included, with six active subjects
According to the company, the products are advanced wound care dressings that create a moist wound healing environment, deactivate harmful wound proteases and promote tissue growth in chronic
The European Federation of Pharmaceutical Industries and Associations (EFPIA)believes that a ban on repackaging will help deter the counterfeiters from entering the legitimate supply chain. The EFPIA also
The study, called Stealth C-2, is the second in a series of clinical trials designed to evaluate the safety and efficacy of nitazoxanide tablets in combination with Pegasys
This trial marks the sixth indication for which Prochymal has been advanced into Phase II or later-stage clinical trials. The Phase II trial will evaluate the safety and
The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active celiac disease subjects adhering to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.